Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Entresto
Pharma
Novartis stands by $5B Pluvicto goal despite EU regulatory setback
Novartis CEO remains committed to Pluvicto and its radioligand approach as potential PSMA bispecific challengers advance.
Angus Liu
Apr 28, 2026 10:10am
Novartis CEO eyes 2026 growth despite record patent cliff
Feb 4, 2026 2:30pm
Newer drugs came to Novartis' aid as top-selling brands stalled
Oct 28, 2025 11:18am
Novartis' Pluvicto picks up speed, delivers another trial win
Jul 17, 2025 10:56am
Novartis asks court for swift decision in Entresto patent case
Jun 6, 2025 10:26am
A closer look at pharma’s top patent losses in 2025
Mar 21, 2025 9:00am
